# Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

> **NCT00219726** · PHASE2 · COMPLETED · sponsor: **Poitiers University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00219726
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2012-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219726, "Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00219726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*